{"id":906,"date":"2022-05-05T23:20:53","date_gmt":"2022-05-05T23:20:53","guid":{"rendered":"https:\/\/alectos.com\/alectos-content\/?page_id=906"},"modified":"2022-05-26T22:03:33","modified_gmt":"2022-05-26T22:03:33","slug":"gba2","status":"publish","type":"page","link":"https:\/\/alectos.com\/alectos-content\/index.php\/gba2\/","title":{"rendered":"GBA2"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-padding-top:100px;--awb-padding-bottom:100px;--awb-background-color:var(--awb-color2);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-justify-content-center fusion-flex-content-wrap\" style=\"max-width:1216.8px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_2_3 2_3 fusion-flex-column\" style=\"--awb-bg-blend:overlay;--awb-bg-size:cover;--awb-width-large:66.666666666667%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.88%;--awb-margin-bottom-large:2%;--awb-spacing-left-large:2.88%;--awb-width-medium:66.666666666667%;--awb-spacing-right-medium:2.88%;--awb-spacing-left-medium:2.88%;--awb-width-small:100%;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-title title fusion-title-1 fusion-sep-none fusion-title-center fusion-title-text fusion-title-size-two\"><h2 class=\"fusion-title-heading title-heading-center fusion-responsive-typography-calculated\" style=\"margin:0;--fontSize:40;line-height:1.3;\">Latest Publications<\/h2><\/div><div class=\"fusion-separator\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:30px;width:100%;max-width:100px;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"--awb-height:20px;--awb-amount:20px;--awb-sep-color:#37c6f3;border-color:#37c6f3;border-top-width:2px;\"><\/div><\/div><div class=\"fusion-text fusion-text-1\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-blend:overlay;--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-blog-shortcode fusion-blog-shortcode-1 fusion-blog-archive fusion-blog-layout-grid-wrapper fusion-blog-pagination fusion-blog-no-images\" style=\"--grid_separator_color:#37c6f3;\"><style type=\"text\/css\">.fusion-blog-shortcode-1 .fusion-blog-layout-grid .fusion-post-grid{padding:20px;}.fusion-blog-shortcode-1 .fusion-posts-container{margin-left: -20px !important; margin-right:-20px !important;}<\/style><div class=\"fusion-posts-container fusion-posts-container-pagination fusion-blog-layout-grid fusion-blog-layout-grid-3 isotope\" data-pages=\"1\" data-grid-col-space=\"40\" style=\"margin: -20px -20px 0;min-height:500px;\"><article id=\"blog-1-post-1091\" class=\"fusion-post-grid post-1091 post type-post status-publish format-standard hentry category-news tag-al01811 tag-biogen tag-gba2 tag-parkinsons\">\n<div class=\"fusion-post-wrapper\" style=\"background-color:rgba(255,255,255,0);border:1px solid var(--awb-color2);border-bottom-width:3px;\"><div class=\"fusion-post-content-wrapper\" style=\"padding:30px 25px 25px 25px;\"><div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/alectos.com\/alectos-content\/index.php\/2022\/06\/06\/biogen-and-alectos-therapeutics-announce-license-and-collaboration-agreement-for-al01811-a-novel-gba2-inhibitor-for-the-potential-treatment-of-parkinsons-disease\/\">Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson\u2019s Disease<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/alectos.com\/alectos-content\/index.php\/author\/administrator\/\" title=\"Posts by Administrator\" rel=\"author\">Administrator<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2022-06-03T12:12:33-07:00<\/span><span>June 6, 2022<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-content-sep sep-double sep-solid\"><\/div><div class=\"fusion-post-content-container\"><p>AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease modifying treatment for Parkinson\u2019s Disease Alectos to receive a $15 million upfront payment and is eligible to receive potential future development [...]<\/p><\/div><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignleft\"><a class=\"fusion-read-more\" href=\"https:\/\/alectos.com\/alectos-content\/index.php\/2022\/06\/06\/biogen-and-alectos-therapeutics-announce-license-and-collaboration-agreement-for-al01811-a-novel-gba2-inhibitor-for-the-potential-treatment-of-parkinsons-disease\/\" aria-label=\"More on Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson\u2019s Disease\">Read More<\/a><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div>\n<\/article>\n<article id=\"blog-1-post-488\" class=\"fusion-post-grid post-488 post type-post status-publish format-standard hentry category-publications tag-gba2 tag-lysosomal-dysfunction tag-npc\">\n<div class=\"fusion-post-wrapper\" style=\"background-color:rgba(255,255,255,0);border:1px solid var(--awb-color2);border-bottom-width:3px;\"><div class=\"fusion-post-content-wrapper\" style=\"padding:30px 25px 25px 25px;\"><div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/alectos.com\/alectos-content\/index.php\/2019\/03\/12\/cytosolic-glucosylceramide-regulates-endolysosomal-function-in-niemann-pick-type-c-disease\/\">Cytosolic Glucosylceramide Regulates Endolysosomal Function in Niemann-Pick type C Disease<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/alectos.com\/alectos-content\/index.php\/author\/emceachern22\/\" title=\"Posts by Administrator\" rel=\"author\">Administrator<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2019-03-12T01:50:21-07:00<\/span><span>March 12, 2019<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-content-sep sep-double sep-solid\"><\/div><div class=\"fusion-post-content-container\"><p>Niemann-Pick type C disease (NPCD) is a neurodegenerative disease associated with increases in cellular cholesterol and glycolipids and most commonly caused by defective NPC1, a late endosomal protein. Using ratiometric probes we find that NPCD [...]<\/p><\/div><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignleft\"><a class=\"fusion-read-more\" href=\"https:\/\/alectos.com\/alectos-content\/index.php\/2019\/03\/12\/cytosolic-glucosylceramide-regulates-endolysosomal-function-in-niemann-pick-type-c-disease\/\" aria-label=\"More on Cytosolic Glucosylceramide Regulates Endolysosomal Function in Niemann-Pick type C Disease\">Read More<\/a><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div>\n<\/article>\n<article id=\"blog-1-post-486\" class=\"fusion-post-grid post-486 post type-post status-publish format-standard hentry category-publications tag-gba2 tag-lysosomal-dysfunction tag-mliv\">\n<div class=\"fusion-post-wrapper\" style=\"background-color:rgba(255,255,255,0);border:1px solid var(--awb-color2);border-bottom-width:3px;\"><div class=\"fusion-post-content-wrapper\" style=\"padding:30px 25px 25px 25px;\"><div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/alectos.com\/alectos-content\/index.php\/2017\/06\/10\/n-butyldeoxynojirimycin-delays-motor-deficits-cerebellar-microgliosis-and-purkinje-cell-loss-in-a-mouse-model-of-mucolipidosis-type-iv\/\">N-Butyldeoxynojirimycin Delays Motor Deficits, Cerebellar Microgliosis, and Purkinje Cell Loss in a Mouse Model of Mucolipidosis type IV<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/alectos.com\/alectos-content\/index.php\/author\/emceachern22\/\" title=\"Posts by Administrator\" rel=\"author\">Administrator<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2017-06-10T01:44:33-07:00<\/span><span>June 10, 2017<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-content-sep sep-double sep-solid\"><\/div><div class=\"fusion-post-content-container\"><p>Mucolipidosis type IV (MLIV) is a lysosomal storage disease exhibiting progressive intellectual disability, motor impairment, and premature death. There is currently no cure or corrective treatment. The disease results from mutations in the gene encoding [...]<\/p><\/div><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignleft\"><a class=\"fusion-read-more\" href=\"https:\/\/alectos.com\/alectos-content\/index.php\/2017\/06\/10\/n-butyldeoxynojirimycin-delays-motor-deficits-cerebellar-microgliosis-and-purkinje-cell-loss-in-a-mouse-model-of-mucolipidosis-type-iv\/\" aria-label=\"More on N-Butyldeoxynojirimycin Delays Motor Deficits, Cerebellar Microgliosis, and Purkinje Cell Loss in a Mouse Model of Mucolipidosis type IV\">Read More<\/a><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div>\n<\/article>\n<article id=\"blog-1-post-479\" class=\"fusion-post-grid post-479 post type-post status-publish format-standard hentry category-news category-publications tag-gba2 tag-lysosomal-dysfunction tag-npc\">\n<div class=\"fusion-post-wrapper\" style=\"background-color:rgba(255,255,255,0);border:1px solid var(--awb-color2);border-bottom-width:3px;\"><div class=\"fusion-post-content-wrapper\" style=\"padding:30px 25px 25px 25px;\"><div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/alectos.com\/alectos-content\/index.php\/2016\/06\/01\/reducing-gba2-activity-ameliorates-neuropathology-in-niemann-pick-type-c-mice\/\">Reducing GBA2 Activity Ameliorates Neuropathology in Niemann-Pick Type C Mice<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/alectos.com\/alectos-content\/index.php\/author\/emceachern22\/\" title=\"Posts by Administrator\" rel=\"author\">Administrator<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2016-06-01T23:22:06-07:00<\/span><span>June 1, 2016<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-content-sep sep-double sep-solid\"><\/div><div class=\"fusion-post-content-container\"><p>The enzyme glucocerebrosidase (GBA) hydrolyses glucosylceramide (GlcCer) in lysosomes. Markedly reduced GBA activity is associated with severe manifestations of Gaucher disease including neurological involvement. Mutations in the GBA gene have recently also been identified as [...]<\/p><\/div><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignleft\"><a class=\"fusion-read-more\" href=\"https:\/\/alectos.com\/alectos-content\/index.php\/2016\/06\/01\/reducing-gba2-activity-ameliorates-neuropathology-in-niemann-pick-type-c-mice\/\" aria-label=\"More on Reducing GBA2 Activity Ameliorates Neuropathology in Niemann-Pick Type C Mice\">Read More<\/a><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div>\n<\/article>\n<article id=\"blog-1-post-484\" class=\"fusion-post-grid post-484 post type-post status-publish format-standard hentry category-publications tag-gaucher tag-gba2 tag-lysosomal-dysfunction\">\n<div class=\"fusion-post-wrapper\" style=\"background-color:rgba(255,255,255,0);border:1px solid var(--awb-color2);border-bottom-width:3px;\"><div class=\"fusion-post-content-wrapper\" style=\"padding:30px 25px 25px 25px;\"><div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/alectos.com\/alectos-content\/index.php\/2014\/03\/17\/glucocerebrosidase-2-gene-deletion-rescues-type-1-gaucher-disease\/\">Glucocerebrosidase 2 Gene Deletion Rescues Type 1 Gaucher Disease<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/alectos.com\/alectos-content\/index.php\/author\/emceachern22\/\" title=\"Posts by Administrator\" rel=\"author\">Administrator<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2014-03-17T01:37:30-07:00<\/span><span>March 17, 2014<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-content-sep sep-double sep-solid\"><\/div><div class=\"fusion-post-content-container\"><p>The inherited deficiency of the lysosomal glucocerebrosidase (GBA) due to mutations in the GBA gene results in Gaucher disease (GD). A vast majority of patients present with nonneuronopathic, type 1 GD (GD1). GBA deficiency causes [...]<\/p><\/div><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignleft\"><a class=\"fusion-read-more\" href=\"https:\/\/alectos.com\/alectos-content\/index.php\/2014\/03\/17\/glucocerebrosidase-2-gene-deletion-rescues-type-1-gaucher-disease\/\" aria-label=\"More on Glucocerebrosidase 2 Gene Deletion Rescues Type 1 Gaucher Disease\">Read More<\/a><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div>\n<\/article>\n<div class=\"fusion-clearfix\"><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-906","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/pages\/906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/comments?post=906"}],"version-history":[{"count":5,"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/pages\/906\/revisions"}],"predecessor-version":[{"id":1247,"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/pages\/906\/revisions\/1247"}],"wp:attachment":[{"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/media?parent=906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}